Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Foxwoods Man, drkazmd65
Search This Board:
Last Post: 11/21/2014 9:43:15 PM - Followers: 159 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: Statement of Changes in Beneficial Ownership (4) 11/07/2014 02:58:41 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 11/05/2014 09:27:10 AM
CVM News: CEL-SCI Enrolls 22 Patients During October in Its Phase III Immunotherapy Head and Neck Cancer Trial 11/03/2014 08:30:00 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/28/2014 04:49:23 PM
CVM News: CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million 10/24/2014 10:09:00 AM
PostSubject
#6215  Sticky Note http://www.marketwatch.com/story/small-companies-lead-the-i-o-class-of-cancer-th majatamata 08/08/14 11:00:50 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#6382   INVESTOPEDIA EXPLAINS 'SEC FORM NT 10-Q' The form 10-Q majatamata 11/21/14 09:43:15 PM
#6381   The quarter ended September 30th . I would Foxwoods Man 11/21/14 10:24:16 AM
#6380   I hope the release of the quarterly report peterose 11/21/14 07:39:14 AM
#6379   where the heck is the quarterly report? Thinking-Longterm 11/20/14 03:08:14 PM
#6378   Ok...now it's getting weird why the quarterly report Foxwoods Man 11/20/14 02:33:09 PM
#6377   Picked up some shares up at .59. Hopefully, peterose 11/18/14 04:06:40 PM
#6376   Not to be too negative here but I Foxwoods Man 11/15/14 06:47:40 AM
#6375   Glad I was able to pickup some in Thinking-Longterm 11/14/14 09:20:09 PM
#6374   ...I would guess that the quarterly report would Foxwoods Man 11/14/14 02:53:53 PM
#6373   The only way this stock goes back above peterose 11/14/14 02:39:24 PM
#6372   I would've never thought this stock would be peterose 11/14/14 02:26:07 PM
#6371   Looks attractive on these levels.. If it stays Thinking-Longterm 11/13/14 06:29:44 PM
#6370   Agreed FM on both parts - the interesting drkazmd65 11/10/14 02:59:57 PM
#6369   Interesting company. Stock went from the $4's to Foxwoods Man 11/10/14 02:45:04 PM
#6368   Somewhat related,.... and a caution as to the drkazmd65 11/10/14 11:18:26 AM
#6367   The last run up was back in February Foxwoods Man 11/10/14 10:46:20 AM
#6366   I can't believe the arbitration is taking so peterose 11/10/14 10:40:08 AM
#6365   Yeah, I'm beginning to think the next PR tprosuper 11/10/14 10:07:11 AM
#6364   That's been going on for years, right? Company PlanTrader 11/07/14 04:49:29 PM
#6363   constant drop in PPS and selling prompted the question. Thinking-Longterm 11/07/14 04:41:13 PM
#6362   That's some "gift" for something not doing all tprosuper 11/07/14 04:37:08 PM
#6361   What prompted the question? tprosuper 11/07/14 04:34:05 PM
#6360   Not sure if it's bought on his own Foxwoods Man 11/07/14 03:47:51 PM
#6359   It was a form 4 filed nov.4 for geert peterose 11/07/14 03:13:14 PM
#6358   geert acquired 2,124,388 shares at .68 I know his peterose 11/07/14 03:08:59 PM
#6357   Bad news coming for CVM? Thinking-Longterm 11/07/14 02:31:14 PM
#6356   Agreed FM. Steadily increasing enrollment numbers over drkazmd65 11/03/14 12:04:54 PM
#6355   Good enrollment number...and announced 29 minutes after my Foxwoods Man 11/03/14 11:01:18 AM
#6354   Apparently it was released FM,... and that number drkazmd65 11/03/14 10:02:43 AM
#6353   I would expect that the monthly enrollment will Foxwoods Man 11/03/14 08:01:17 AM
#6352   The one million offering is a Reg. Direct Turney 10/26/14 07:19:31 PM
#6351   I agree.. They need a good enrollment number majatamata 10/26/14 02:45:11 PM
#6350   I still thinl cel sci will receive at peterose 10/25/14 09:11:11 PM
#6349   This stock can never hold its value. CVM Thinking-Longterm 10/25/14 05:34:46 PM
#6348   Obviously I am missing your point since 6/1 Foxwoods Man 10/24/14 02:18:54 PM
#6347   I know about the 6Million. but why the Turney 10/24/14 01:15:45 PM
#6346   CEL-SCI Corporation to Raise $1 Million in Registered Foxwoods Man 10/24/14 08:59:39 AM
#6345   I'm wondering WHY they only decided to raise Turney 10/23/14 04:32:48 PM
#6344   Out a .695.... learning curve 10/23/14 11:21:01 AM
#6343   Exactly tprosuper. drkazmd65 10/22/14 10:37:44 AM
#6342   I got filled @ .17. I won't worry Turney 10/21/14 01:28:02 PM
#6341   In lieu of a marketable product at this tprosuper 10/21/14 11:04:54 AM
#6340   I added....price % drop was enough to average learning curve 10/21/14 11:00:22 AM
#6339   This company is a pos ... They do Spike5 10/21/14 09:52:17 AM
#6338   Put in an order for 5000 more warrants Turney 10/21/14 09:47:47 AM
#6336   why put a cap/ overhang of 4 years learning curve 10/20/14 08:26:59 PM
#6335   After Hours - Timberrrrr! kpisme 10/20/14 08:07:57 PM
#6334   What is next? learning curve 10/20/14 06:39:13 PM
#6333   Correct...but I DO know that this ain't gonna happen: Foxwoods Man 10/17/14 04:49:12 PM
#6332   You don't know that for sure, what about Turney 10/17/14 04:37:44 PM
PostSubject